Scilex (SCLX) Total Debt (2020 - 2026)
Scilex (SCLX) total debt from Mar 31, 2020 to Mar 31, 2026. The current Scilex (SCLX) total debt is $548M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Total Debt
Total Debt
Scilex (SCLX) Total Debt CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | +58.47% |
| 3 Years TTM | +115.81% |
| 5 Years TTM | +538.67% |
| All Time TTM | +538.84% |
Annual Total Debt change of Scilex (SCLX)
| Year | Total Debt | Change |
|---|---|---|
| 2025 | $577M | +101.94% |
| 2024 | $286M | +4.13% |
| 2023 | $274M | +445.34% |
| 2022 | $50M | +27838.89% |
| 2020 | $180K | N/A |
Comparison Scilex (SCLX) total debt with competitors
Scilex (SCLX) total debt is $547.71M.
| Ticker | Name | Total Debt | Upside |
|---|---|---|---|
| MIRA | Mira Pharmaceuticals Inc | $114761.00 | -99.98% |
| NSRX | Nasus Pharma Ltd | $2.24M | -99.59% |
| MDCX | MDCorp | $6.00M | -98.90% |
| MDCXW | Medicus Pharma Ltd warrant | $6.00M | -98.90% |
| AMRN | Amarin Corp | $196.35M | -64.15% |
| BIIB | Biogen Inc | $10.83B | +1877.58% |
| OGN | Organon & Company | $12.09B | +2107.92% |
| GRFS | Grifols SA | $12.24B | +2135.44% |
| SNY | Sanofi | $54.88B | +9920.08% |
| GSK | GSK Plc | $59.93B | +10842.10% |
| BMY | Bristol-Myers Squibb Company | $66.37B | +12018.46% |
| AZN | Astrazeneca plc | $66.63B | +12065.38% |
| NVS | Novartis AG | $79.61B | +14434.15% |
| PFE | Pfizer Inc | $117.21B | +21300.74% |
| JNJ | Johnson & Johnson | $119.71B | +21756.09% |
| NVO | Novo Nordisk | $356.16B | +64926.38% |